BriaCell Therapeutics Corp. Stock price

Equities

BCT

CA1079301091

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:59:51 2024-03-18 pm EDT 5-day change 1st Jan Change
3.91 CAD -2.25% Intraday chart for BriaCell Therapeutics Corp. -3.22% -49.87%
Sales 2024 * - Sales 2025 * - Capitalization 46.13M 62.47M
Net income 2024 * -13M -17.6M Net income 2025 * -22M -29.79M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-3.65 x
P/E ratio 2025 *
-2.75 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.83%
More Fundamentals * Assessed data
Dynamic Chart
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference MT
BriaCell Announces Strong Clinical Data in Breast Cancer Patients MT
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case CI
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth DJ
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing CI
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer MT
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients MT
BriaCell Brief: Has Reported 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients; Comes After Shares Jumped 18% on Wednesday MT
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients CI
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset CI
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium MT
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS CI
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen CI
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND CI
More news
1 day-2.25%
1 week-3.22%
Current month-15.91%
1 month-9.28%
3 months-28.91%
6 months-50.94%
Current year-49.87%
More quotes
1 week
3.65
Extreme 3.65
4.10
1 month
3.65
Extreme 3.65
4.94
Current year
3.65
Extreme 3.65
8.00
1 year
3.65
Extreme 3.65
10.45
3 years
3.50
Extreme 3.5
15.75
5 years
0.00
Extreme 0
45.00
10 years
0.00
Extreme 0
141.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 16-10-31
Director of Finance/CFO 52 16-01-31
Chief Tech/Sci/R&D Officer 53 21-04-30
Members of the board TitleAgeSince
Director/Board Member 62 16-05-09
Director/Board Member 51 21-08-30
Director/Board Member 71 18-03-06
More insiders
Date Price Change Volume
24-03-18 3.91 -2.25% 17,560
24-03-15 4 -0.99% 14,291
24-03-14 4.04 +1.25% 10,700
24-03-13 3.99 -1.48% 12,508
24-03-12 4.05 +0.25% 3,353

Delayed Quote Toronto S.E., March 18, 2024 at 03:59 pm EDT

More quotes
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.91
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock BriaCell Therapeutics Corp. - Toronto S.E.